1/16
04:01 pm
mtva
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
Low
Report
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
1/15
09:32 am
mtva
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
High
Report
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
1/6
01:30 pm
mtva
MetaVia (NASDAQ:MTVA) had its price target raised by analysts at HC Wainwright from $12.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
MetaVia (NASDAQ:MTVA) had its price target raised by analysts at HC Wainwright from $12.00 to $40.00. They now have a "buy" rating on the stock.
1/5
08:41 am
mtva
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile [Yaho
High
Report
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile [Yaho
1/5
08:30 am
mtva
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
Medium
Report
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
12/29
08:31 am
mtva
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
Low
Report
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
12/22
08:31 am
mtva
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
High
Report
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
12/2
09:06 am
mtva
MetaVia Inc. Announces 1-for-11 Reverse Stock Split [Yahoo! Finance]
Low
Report
MetaVia Inc. Announces 1-for-11 Reverse Stock Split [Yahoo! Finance]
12/2
08:45 am
mtva
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
Medium
Report
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
11/7
08:31 am
mtva
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
Medium
Report
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
11/6
08:31 am
mtva
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/4
04:25 pm
mtva
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025 [Yahoo! Finance]
Medium
Report
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025 [Yahoo! Finance]
11/4
04:01 pm
mtva
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
High
Report
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
10/27
08:31 am
mtva
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
Low
Report
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
10/25
12:09 pm
mtva
MetaVia (NASDAQ:MTVA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MetaVia (NASDAQ:MTVA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.